MarketCap
Castle Biosciences CSTL
$ 32.49
-4.86%
Facebook
X
Telegram
Castle Biosciences Total Liabilities | CSTL
Annual Total Liabilities Castle Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 M | 75.4 M | 62.1 M | 48.2 M | 50.8 M | 23.6 M | 34.6 M | 32.5 M | 24.1 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 23.6 M | 51 M |
Quarterly Total Liabilities Castle Biosciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101 M | 91.1 M | 86.4 M | 108 M | 95.7 M | 89.4 M | 61.4 M | 75.4 M | 73.5 M | 63.4 M | 56 M | 62.1 M | 50.2 M | 46.6 M | 41.7 M | 48.2 M | 46.4 M | 36.7 M | 47.1 M | 50.8 M | 22 M | 19.6 M | 18.7 M | 23.6 M | 43.8 M | 43.9 M | 32.3 M | 34.6 M | 30.9 M | 36.9 M | 34.6 M | 32.5 M | 32.5 M | 32.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 18.7 M | 52 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 338.13 | 8.07 % | $ 16.8 B |  USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
3.11 B | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
2.4 B | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
62.8 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
115 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
42.5 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
2.52 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
40.6 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
23.3 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
338 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
59.7 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
4.7 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
15.8 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
3.19 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
135 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
366 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
3.59 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
5.99 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
89.9 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
29.2 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
455 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
4.13 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 204.67 | 1.5 % | $ 16.1 B | Irlanda |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
285 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
339 M | $ 5.97 | -5.17 % | $ 553 M | USA |